
    
      The study will be conducted in two parts. The first part is efficacy exploration and the
      second part is efficacy verification. During the course of efficacy exploration, 33 subjects
      will be enrolled to preliminarily evaluate the safety and efficacy of MRG002. The second part
      will be adjusted according to the result of the first part. 29 subjects are planned to be
      enrolled. Considering the dropout rate of 10%, approximately 33 subjects are planned to be
      enrolled. A total of 66 subjects are planned to be enrolled in efficacy exploration and
      verification.
    
  